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Stevens Johnson Syndrome in Pakistan: a Ten-Year Survey 
Y. I. Ahmed, S. Azeem, O. Khan, T. H. Majid, D. Ahmed, A. Amin, A. Mahmood, K. Hameed 
Department of Medicine, The Aga Khan University Hospital, Karachi. 
Abstract 
Objective: A pre-tested questionnaire-based, retrospective study to highlight the causative factors, mode of 
presentation, complications and outcome of patients with Stevens Johnson syndrome. 
Setting: Aga Khan University Hospital over a 10 year period. 
Methods: All case records with a diagnosis of Steven Johnson Syndrome in the period 1990 to 2000 were 
retrospectively reviewed.  Data was retrieved on a comprehensive questionnaire.  The demographic variatbles 
and drugs taken within the previous 21 days were noted. Date analysis was done by Epi-Info Version 6.0. 
Results: Of the 101studied patient files,  the most common offender was found to be the Penicillins as a group 
and Sulfadoxine-Pyrimethamine (Fansidar) when considering all drugs individually.  Most common complications 
included electrolyte disturbances (13.9%) and congestive heart failure (6.9%).  Mortality rate was high at 10.1%. 
Conclusion: SJS was found to be a rare condition but having a mortality rate of 10.1%.  As it can be induced by 




Stevens Johnson Syndrome (SJS) is a generalized, multi-
systemic hypersensitivity reaction usually to drug exposure in 
which skin and mucous membrane lesions are early 
manifestations. It was first fully described by Stevens and 
Johnson in 19221 and is a potentially life threatening illness 
considered to be part of the erythema multiform spectrum. 
Usually it is a self-limiting disease. No studies, pertaining to a 
large number of patients over a significant time period have been 
done in Pakistan that have investigated the eitiologies and course 
of Stevens Johnson Syndrome. Western reports represent their 
local experiences and drug prescribing.  In addition to this, and 
probably most importantly, the mortality rate is not known in this 
part of the world. 
Patients and Methods 
Case Selection 
A retrospective review of all the cases seen at the Aga 
Khan University Hospital, with a diagnosis of Stevens Johnson 
Syndrome (SJS) during 1990-2000 was carried out. Data was 
obtained from the patients' files. A total of 187 patients were 
identified with a discharge diagnosis of Stevens Johnson 
syndrome according to the International Classification of 
Diseases code ICD-9-CM 695.1. Since the ICD-9-CM code for 
erythema multiforme includes other illnesses in addition to 
Stevens Johnson syndrome and because these illnesses are 
occasionally misdiagnosed, the patients' primary medical records 
were sought to confirm whether a skin disease compatible with 
Stevens Johnson syndrome was present or not. Stevens Johnson 
syndrome was identified according to the following strict criteria 
of: (1) involvement of at least 2 different mucous membrane 
sites; (2) erosions covering >10% but <20% of the body surface 
area and (3) visible iris and target lesions.   These criteria were 
assessed by reviewing patient charts, where these lesions had 
been professionally and precisely documented by a 
dermatologist. 
Data Collection 
To gather clinical information, comprehensive data 
collection was carried out, using a questionnaire that  was 
designed after an extensive literature review using the University 
Library, Medline and the Internet. The questionnaire, amongst 
other things, included demographic variables, history of drug 
intake, signs and symptoms and ultimate outcome. A drug 
causally related to the condition was defined as every drug that 
had been taken close enough prior to the onset of any symptom 
(i.e., 21 days). 
Final year medical students at The Aga Khan University 
undertook the task of data collection.  The biostatistical program, 
Epi-Info (version 6.0) was used to analyze the gathered data. 
Frequencies and percentages of relevant variables were obtained 
and documented. The analysis is described below.  
Results 
Atotal of 101 patients were identified. The incidence of 
SJS in the population was found to be 1.89 cases per million per 
year. The mean age at presentation was 26.4 years with a standard 
deviation of 19.8 years.  There were 62 females and 39 males. 
Amongst the female patients, 4 were pregnant at the time.  Only 
4 of the patients were from outside the city. 
The predominant mode of presentation was primary 








SJS secondary to treatment for another illness.  Previous history 
of SJS was positive in a total of 9 patients. The duration of 
hospital stay was 10.2 days with a standard deviation of 8.9 
days. 
Of the 101 patients included in this study, 93 gave a 
positive history of drug intake prior to developing the signs and 
symptoms of Stevens Johnson Syndrome. Seven 
 
 
patients could not provide information regarding the most likely 
offender. Only one patient gave a history of meningitis 
vaccination. No other vaccination history was given. The exact 
dose of the administered drug was known in 48 cases, mode of 
administration was oral in 95 patients and parenteral in 6. Twelve 
patients gave a history of previous exposure to the offending 
agent. Signs and symptoms (Figures 1and 2), complications 
(Figure 3) and identity of offending drugs (Figure 4) are given in 
their respective figures.  Ninety patients were discharged from 
the hospital after treatment while one patient was shifted to 
another hospital. Ten patients died giving a mortality rate of 
10.1%. Mortality was not affected by the type of drug 
responsible. 
Discussion 
Stevens Johnson Syndrome (SJS) is an infrequently 
encountered condition and we were able to review 101 individual 
cases in a 10-year period at The Aga Khan University Hospital. 
The study was consistent with other literature regarding age, that 
it affected mainly the pediatric age group and young adults. 
However, one particular study we came across did not achieve 
this result.2 
Our study revealed a male to female ratio of about 2:3. 
Studies vary in this matter. Some quote male sex as a well-known 
risk factor for the condition3 whereas some document that being 
female carries a higher risk for these types of adverse drug 
reactions.4-6 
Astudy of a primary presentation versus a secondary one 
was undertaken to see if other illnesses predispose to SJS. 
However, 96 of the patients presented with primary SJS and no 
significant conclusion could be determined.  
Amongst our 101 patients, 92 had no previous history of 
SJS. A previous attack is a known risk factor for the development 
of SJS.3 The general risk of recurrence of SJS is said to be about 
37%, but our figures suggest a much lower percentage of about 
8.9%. 
Of the 101 cases reviewed, drugs were clearly one of 
Of the 101 cases reviewed, drugs were clearly one of the 
major offenders, contributing to about 93.9% of all cases, as 
compared to 43% in a study in the United States7 and 54.5% in 
Malaysia.8 This high incidence could be attributed to irrational, 
unnecessary and easy 'over the counter' use of medicines in this 
part of the world. Drugs are followed by infections (5.9%), 
vaccines (0.1%) and the unknown category also being 0.1%.  
Amongst drugs (Figure 4), antibiotics were the cause of 
SJS in 67 cases (66.3%) making it the most common category of 
drug. This tallies with some previously published studies.5,9-11 
Amongst them the Penicillins had the highest incidence (30 
cases) and the Sulphonamides had the second highest incidence 
(26 cases) of causing SJS. The remaining drugs comprised of 
Cepahalosporins, Macrolides, Tetracyclics and Quinolones.  
When the drugs were analyzed on an individual basis (i.e. 
taken out of their groups), Sulfadoxine-Pyrimethamine 
(Fansidar) had the highest association with SJS; seen in 19 cases. 
This is probably due to the high incidence of malaria endemic in 
these parts of the world necessitating the use of cheaper anti-
malarials. This statement can be supported by the high incidence 
of SJS in the inhabitants of Beira, Mozambique who were given 
Fansidar for mass prophylaxis against cholera12 and in a study of 
Swiss travelers using the same drug, they reported severe 
cutaneous adverse reactions one thirtieth as large.13 
NSAIDS accounted for 14 cases of SJS, which is 
comparatively lower than other studies10,14,15, where NSAIDS 
were responsible for about 50-74% of SJS cases. This could be 
due to their relatively higher price in this country and cheaper 
alternatives. Other drugs that caused single cases of SJS consisted 
of Metronidazole, Diltiazem, Mebendazole and even one 
reported case due to the ingestion of Smarties®. A study in 
Thailand concluded that antituberculous drugs ranked third in 
overall incidence when causing SJS but no case was reported 
involving an antituberculous drug in our study even though 
Pakistan is considered to be an endemic region for the disease. 
This is in sharp contrast to a study in neighboring India.16 
A cause for the high incidence of drug related SJS could 
be due to the fact that the indication of antibiotic use in some 
cases may have been for the treatment of early signs and 
symptoms of SJS due to other drugs. In one case, symptoms 
deteriorated following Amoxicillin use and the general 
practitioner involved increased the dose of the offending drug for 
a further 7 days. 
Concerning signs and symptoms (Figures 1 and 2), fever 
was seen in 88 cases whereas ocular involvement occurred in 57 
patients, making them the commonest nondermatological 
manifestations of SJS in our study group. 
This coincides with some studies done abroad.8 However, 
patients with SJS in this study also presented with some 
symptoms not found in standard literature or text. These included 
dysuria (9 cases), edema (8 cases), dysphagia (6 cases) and 
diarrhea (6 cases). The significance of these previously 
undocumented outcomes following SJS requires further 
investigations.  
As regards to the complications during hospitalization 
(Figure 3), the most commonly found ones were electrolyte 
disturbances (14 cases) and congestive heart failure leading to 
pulmonary edema (7 cases). Some complications, not previously 
documented in standard medical literature, included 
hematochezia (5 cases), hyperglycemia (3 cases) and depression 
(1 case). Our complication rate was 59.4%. The study had a 
relatively low occurrence of permanent visual changes in patients 
following SJS. The rate of occurrence of  permanent visual 
change was 1.9%, whereas studies have reported the rate as high 
as to 20%.2 Regular referrals and follow-ups by the 
ophthalmologists were vital for this outcome.  
The mortality in this group of patients was 10.1%, which 
roughly coincides with studies done in the West where it is 4.5-
15% of the patients.  Acute hepatic failure was responsible for 2 
deaths and sepsis was the cause of 1 mortality. No association 
was found between the length of stay in the hospital and eventual 
outcome. An interesting fact which came up in the analysis was 
that one third of the patients that died had taken Amoxicillin as 
the initial offender for SJS.  
Conclusion 
One hundred and one cases in ten years indicates that SJS 
is a relatively rare condition.  It is perhaps a first step for further 
studies in the future, comparing results with other countries in the 
region or even with that of toxic epidermal necrolysis (TEN), its 
deadly counterpart. With a 10.1% mortality rate, which correlates 
with the West, this syndrome should not be underestimated or 
overlooked SJS is a hypersensitive reaction to a varied range of 
etiologic factors and a large number of drugs may induce it. As 
such, knowledge about this condition  should modify a 
physician's perception of the risk benefit balance of virtually any 
drug. To investigate this further, a larger study would be needed.  
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